VA awards $4.1M contract for cell-free DNA testing to Eurofins Transplant Genomics

Contract Overview

Contract Amount: $41,250 ($41.3K)

Contractor: Eurofins Transplant Genomics, LLC

Awarding Agency: Department of Veterans Affairs

Start Date: 2026-04-01

End Date: 2027-03-31

Contract Duration: 364 days

Daily Burn Rate: $113/day

Competition Type: COMPETED UNDER SAP

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: DONOR-DERIVED CELL-FREE DNA (DD-CFDNA) TESTING

Place of Performance

Location: BRONX, BRONX County, NEW YORK, 10468

State: New York Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $41,250 to EUROFINS TRANSPLANT GENOMICS, LLC for work described as: DONOR-DERIVED CELL-FREE DNA (DD-CFDNA) TESTING Key points: 1. Contract awarded for specialized diagnostic testing, indicating a need for advanced medical capabilities. 2. The contract is a delivery order under a larger agreement, suggesting a phased approach to procurement. 3. Fixed-price contract type aims to control costs and provide budget certainty. 4. The duration of the contract is one year, allowing for periodic reassessment of needs. 5. The awarding agency is the Department of Veterans Affairs, highlighting a focus on veteran healthcare. 6. The North American Industry Classification System (NAICS) code 621511 points to medical laboratory services.

Value Assessment

Rating: good

The contract value of $4.1 million for DD-CFDNA testing appears reasonable for specialized laboratory services. Benchmarking against similar contracts for advanced genetic testing would provide a more precise value-for-money assessment. The firm fixed-price structure suggests a degree of cost control. However, without specific details on the volume of tests or the exact scope of services, a definitive value assessment is challenging. The contract's duration of one year allows for flexibility and potential renegotiation if market conditions or service needs change.

Cost Per Unit: N/A

Competition Analysis

Competition Level: limited

The contract was competed under SAP (Simplified Acquisition Procedures), which typically implies a less extensive competition than full and open solicitations. While the specific number of bidders is not provided, SAP is often used for procurements below certain dollar thresholds and may involve fewer offerors. This limited competition could potentially lead to less aggressive pricing compared to a broader solicitation, though it can also expedite the acquisition process for essential services.

Taxpayer Impact: For taxpayers, limited competition under SAP may mean a slightly higher price than could be achieved through a wider bidding process. However, the efficiency gains from SAP can sometimes offset this, especially for urgent or specialized needs.

Public Impact

Veterans will benefit from access to advanced diagnostic testing for donor-derived cell-free DNA, aiding in transplant monitoring and management. The services delivered will support the VA's mission to provide comprehensive healthcare to its beneficiaries. The contract's geographic impact is centered in New York, where the contractor is located, but the services will likely be utilized by veterans nationwide through the VA system. This contract supports specialized roles within the medical laboratory and healthcare technology sectors.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Limited competition under SAP may not yield the best possible pricing for taxpayers.
Lack of detailed performance metrics in the provided data makes it difficult to assess service quality.
The one-year duration might necessitate frequent re-competition, leading to administrative overhead.

Positive Signals

Firm fixed-price contract provides cost certainty for the VA.
Award to a specialized provider like Eurofins Transplant Genomics suggests access to advanced technology.
Contract supports critical healthcare needs for veterans, aligning with the VA's mission.

Sector Analysis

The market for advanced molecular diagnostics, including cell-free DNA testing, is a rapidly growing segment within the broader healthcare and biotechnology sector. This contract falls under medical laboratory services, a critical component of healthcare delivery. The global market for transplant diagnostics is expanding due to increasing organ transplant rates and the need for effective post-transplant monitoring. Spending in this area is driven by technological advancements and the demand for personalized medicine.

Small Business Impact

The provided data does not indicate any specific small business set-aside or subcontracting requirements for this contract. As the award was made to Eurofins Transplant Genomics, LLC, a specific entity, further analysis would be needed to determine if they have a subcontracting plan that benefits small businesses. Without this information, the direct impact on the small business ecosystem is unclear.

Oversight & Accountability

Oversight for this contract would primarily reside with the Department of Veterans Affairs contracting officers and program managers. They are responsible for ensuring compliance with contract terms, monitoring performance, and approving payments. The firm fixed-price nature of the contract provides a degree of financial oversight. Transparency is facilitated through contract databases, but detailed operational oversight information is typically internal to the agency.

Related Government Programs

VA Laboratory Services Contracts
Medical Diagnostic Testing Contracts
Cell-Free DNA Analysis Programs
Transplant Patient Monitoring Services

Risk Flags

Limited competition may impact price.
Potential for service disruption if contractor performance falters.
Need for ongoing monitoring of technological advancements in DD-CFDNA testing.

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $41,250 to EUROFINS TRANSPLANT GENOMICS, LLC. DONOR-DERIVED CELL-FREE DNA (DD-CFDNA) TESTING

Who is the contractor on this award?

The obligated recipient is EUROFINS TRANSPLANT GENOMICS, LLC.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $41,250.

What is the period of performance?

Start: 2026-04-01. End: 2027-03-31.

What is the specific type of DD-CFDNA testing being procured, and what is its clinical significance for transplant patients?

The specific type of Donor-Derived Cell-Free DNA (DD-CFDNA) testing procured under this contract is likely focused on monitoring for organ transplant rejection. DD-CFDNA analysis involves detecting and quantifying fragments of DNA released from a transplanted organ into the recipient's bloodstream. Elevated levels of donor DNA can serve as an early indicator of potential organ rejection, allowing clinicians to intervene with immunosuppressive therapy or other treatments before irreversible damage occurs. This non-invasive method complements traditional biopsy procedures, potentially reducing patient risk and improving transplant outcomes. The clinical significance lies in its ability to provide timely, actionable information for managing transplant recipients, thereby enhancing graft survival rates and patient quality of life.

How does the $4.1 million contract value compare to historical VA spending on similar diagnostic tests?

Comparing the $4.1 million contract value for DD-CFDNA testing to historical VA spending requires access to detailed historical procurement data for similar services. Without specific historical figures for DD-CFDNA testing or comparable advanced molecular diagnostics within the VA, a direct comparison is difficult. However, the value suggests a significant investment in this specialized area. The VA's overall budget for medical services is substantial, and contracts for advanced diagnostics are expected to represent a growing portion as technology evolves. A comprehensive analysis would involve tracking spending trends for laboratory services, genetic testing, and transplant-related diagnostics over several fiscal years to identify patterns and assess if this award represents an increase, decrease, or stable level of investment.

What are the key performance indicators (KPIs) that the VA will use to evaluate the contractor's performance?

While specific KPIs are not detailed in the provided contract abstract, typical performance indicators for medical laboratory services like DD-CFDNA testing would likely include turnaround time for test results, accuracy and reliability of results (e.g., concordance with other diagnostic methods or biopsy results), specimen handling and integrity, reporting clarity, and overall customer satisfaction from VA medical facilities. The VA would expect the contractor to meet established quality control standards and regulatory requirements (e.g., CLIA certification). Performance would also be assessed against the scope of work, ensuring all contracted tests are performed correctly and reported within agreed-upon timeframes. Failure to meet these KPIs could result in corrective actions or impact future contract awards.

What is the track record of Eurofins Transplant Genomics, LLC in providing similar services to government agencies?

Eurofins Transplant Genomics, LLC is a specialized entity within the broader Eurofins Scientific network, known for its focus on transplant diagnostics. Information regarding their specific track record with government agencies, particularly the VA, would typically be found in contract databases and performance assessment reports (e.g., Contractor Performance Assessment Reporting System - CPARS). As a company operating in a highly regulated field, they are expected to adhere to stringent quality and compliance standards. Their ability to secure this VA contract suggests they have met the agency's requirements, potentially including prior experience or demonstrated capability in providing advanced molecular diagnostic services. A deeper dive into their contract history would reveal the extent and nature of their government work.

What are the potential risks associated with relying on a single delivery order for this critical diagnostic service?

Relying on a single delivery order, even if it falls under a larger competed contract, can introduce several risks. One primary risk is the potential for service disruption if the contractor faces operational issues, financial instability, or fails to meet performance standards. Another risk is the lack of ongoing competitive pressure, which might lead to complacency or less favorable pricing in subsequent periods if the contract is extended or re-competed without significant market engagement. Furthermore, if the technology or clinical needs evolve rapidly, a single, potentially long-term delivery order might not be agile enough to adapt, requiring modifications or new procurements. The VA mitigates some of these risks through contract oversight, performance monitoring, and the ability to potentially terminate for default, but the inherent risk of a singular focus remains.

Industry Classification

NAICS: Health Care and Social Assistance › Medical and Diagnostic Laboratories › Medical Laboratories

Product/Service Code: MEDICAL SERVICES › LABORATORY TESTING SERVICES

Competition & Pricing

Extent Competed: COMPETED UNDER SAP

Solicitation Procedures: SIMPLIFIED ACQUISITION

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 18000 W 99TH ST STE 100, LENEXA, KS, 66219

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Small Business, Special Designations

Financial Breakdown

Contract Ceiling: $41,250

Exercised Options: $41,250

Current Obligation: $41,250

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36C24226D0045

IDV Type: IDC

Timeline